196 related articles for article (PubMed ID: 19249226)
1. Molecular target therapy for gastroenteropancreatic endocrine tumours: biological rationale and clinical perspectives.
Capurso G; Fazio N; Festa S; Panzuto F; De Braud F; Delle Fave G
Crit Rev Oncol Hematol; 2009 Nov; 72(2):110-24. PubMed ID: 19249226
[TBL] [Abstract][Full Text] [Related]
2. Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours.
Modlin IM; Pavel M; Kidd M; Gustafsson BI
Aliment Pharmacol Ther; 2010 Jan; 31(2):169-88. PubMed ID: 19845567
[TBL] [Abstract][Full Text] [Related]
3. Five patients with malignant endocrine tumors treated with imatinib mesylate (Glivec).
Kindmark H; Janson ET; Gustavsson B; Eriksson C; Larsson G; Granberg D; Kozlowacki G; Skogseid B; Welin S; Oberg K; Eriksson B
Acta Oncol; 2010; 49(1):100-1. PubMed ID: 20100145
[No Abstract] [Full Text] [Related]
4. Treatment of advanced endocrine gastroenteropancreatic tumours using radiolabelled somatostatin analogues.
Van Eijck CH
Br J Surg; 2005 Nov; 92(11):1333-4. PubMed ID: 16237740
[No Abstract] [Full Text] [Related]
5. Novel therapeutic agents for the treatment of gastroenteropancreatic neuroendocrine tumors.
Pavel ME; Wiedenmann B
Horm Metab Res; 2011 Nov; 43(12):844-53. PubMed ID: 22105475
[TBL] [Abstract][Full Text] [Related]
6. Review article: future therapies for management of metastatic gastroenteropancreatic neuroendocrine tumours.
Srirajaskanthan R; Toumpanakis C; Meyer T; Caplin ME
Aliment Pharmacol Ther; 2009 Jun; 29(11):1143-54. PubMed ID: 19298583
[TBL] [Abstract][Full Text] [Related]
7. [New perspectives in diagnosis and therapy of endocrine gastroenteropancreatic (GEP) tumors with somatostatin analogues].
Rubello D; Rufini V; De Carlo E; Martini C; Calcagni ML; Sicolo N; Troncone L; Casara D
Minerva Endocrinol; 2003 Dec; 28(4):259-96. PubMed ID: 14752399
[TBL] [Abstract][Full Text] [Related]
8. Novel anticancer agents in clinical trials for well-differentiated neuroendocrine tumors.
Faivre S; Sablin MP; Dreyer C; Raymond E
Endocrinol Metab Clin North Am; 2010 Dec; 39(4):811-26. PubMed ID: 21095547
[TBL] [Abstract][Full Text] [Related]
9. Esophagogastric cancer: targeted agents.
Ku GY; Ilson DH
Cancer Treat Rev; 2010 May; 36(3):235-48. PubMed ID: 20122806
[TBL] [Abstract][Full Text] [Related]
10. Gastroenteropancreatic neuroendocrine tumors: update on therapeutics.
Ganetsky A; Bhatt V
Ann Pharmacother; 2012 Jun; 46(6):851-62. PubMed ID: 22589450
[TBL] [Abstract][Full Text] [Related]
11. [Gastroenteropancreatic neuroendocrine tumours (carcinoid tumours): definition, clinical aspects, diagnosis and therapy].
Bodelier AG; Haak HR
Ned Tijdschr Geneeskd; 2006 Aug; 150(34):1868-72. PubMed ID: 16970007
[TBL] [Abstract][Full Text] [Related]
12. Therapy innovations: tyrosine kinase inhibitors for the treatment of pancreatic neuroendocrine tumors.
Raymond E; Hobday T; Castellano D; Reidy-Lagunes D; García-Carbonero R; Carrato A
Cancer Metastasis Rev; 2011 Mar; 30 Suppl 1():19-26. PubMed ID: 21308478
[TBL] [Abstract][Full Text] [Related]
13. Systemic Therapies for Advanced Gastrointestinal Carcinoid Tumors.
Mulvey CK; Bergsland EK
Hematol Oncol Clin North Am; 2016 Feb; 30(1):63-82. PubMed ID: 26614369
[TBL] [Abstract][Full Text] [Related]
14. Systemic chemotherapy of advanced digestive neuroendocrine tumours.
Rougier P; Ducreux M
Ital J Gastroenterol Hepatol; 1999 Oct; 31 Suppl 2():S202-6. PubMed ID: 10604131
[TBL] [Abstract][Full Text] [Related]
15. mTOR inhibition, a potential novel approach for bronchial carcinoids.
Dong M; Yao JC
Endocr Relat Cancer; 2011 Jun; 18(3):C15-8. PubMed ID: 21427170
[TBL] [Abstract][Full Text] [Related]
16. [Treatment of neuroendocrine tumours of the gastrointestinal tract].
Hansen CP; Langer S; Frevert S; Mortensen J; Kjaer A; Knigge U
Ugeskr Laeger; 2010 Oct; 172(43):2942-5. PubMed ID: 21040671
[TBL] [Abstract][Full Text] [Related]
17. Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms.
Grozinsky-Glasberg S; Shimon I; Korbonits M; Grossman AB
Endocr Relat Cancer; 2008 Sep; 15(3):701-20. PubMed ID: 18524947
[TBL] [Abstract][Full Text] [Related]
18. [Neuroendocrine tumors: the age of targeted therapies].
Capdevila J; Argilés G; Mulet-Margalef N; Tabernero J
Endocrinol Nutr; 2012; 59(7):438-51. PubMed ID: 22565119
[TBL] [Abstract][Full Text] [Related]
19. Treatment of endocrine gastroenteropancreatic tumors with somatostatin analogues.
Fehmann HC; Wulbrand U; Arnold R
Recent Results Cancer Res; 2000; 153():15-22. PubMed ID: 10626286
[TBL] [Abstract][Full Text] [Related]
20. New targets and therapeutic approaches for endocrine malignancies.
Fassnacht M; Kreissl MC; Weismann D; Allolio B
Pharmacol Ther; 2009 Jul; 123(1):117-41. PubMed ID: 19374919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
